{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:26:38Z","timestamp":1780471598877,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":166,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.riam.2021.04.002","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T01:20:46Z","timestamp":1623460846000},"page":"101-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral"],"prefix":"10.1016","volume":"38","author":[{"given":"Bego\u00f1a","family":"Monge-Maillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"L\u00f3pez-V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2021.04.002_bib0210","doi-asserted-by":"crossref","first-page":"e0008319","DOI":"10.1371\/journal.pntd.0008319","article-title":"Prognostic factors for mortality among patients with visceral leishmaniasis in East Africa: Systematic review and meta-analysis","volume":"14","author":"Abongomera","year":"2020","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0215","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/CMR.00061-07","article-title":"The relationship between leishmaniasis and AIDS: The second 10years","volume":"21","author":"Alvar","year":"2008","journal-title":"Clin Microbiol Rev."},{"key":"10.1016\/j.riam.2021.04.002_bib0220","first-page":"25","article-title":"Efficacy and safety of liposomal amphotericinB (AmBisome) for visceral leishmaniasis in endemic developing countries","volume":"76","author":"Berman","year":"1998","journal-title":"Bull World Health Organ."},{"key":"10.1016\/j.riam.2021.04.002_bib0225","first-page":"75","article-title":"Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial","volume":"87","author":"Davidson","year":"1994","journal-title":"Q J Med."},{"key":"10.1016\/j.riam.2021.04.002_bib0230","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/clinids\/22.6.938","article-title":"Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)","volume":"22","author":"Davidson","year":"1996","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0235","doi-asserted-by":"crossref","first-page":"e0006988","DOI":"10.1371\/journal.pntd.0006988","article-title":"A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia","volume":"13","author":"Diro","year":"2019","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0240","doi-asserted-by":"crossref","first-page":"e0007132","DOI":"10.1371\/journal.pntd.0007132","article-title":"Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: A prospective cohort study in Ethiopia","volume":"13","author":"Diro","year":"2019","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0245","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1695-4033(03)78776-1","article-title":"Short course treatment for visceral leishmaniasis with liposomal amphotericinB in immunocompetent patients","volume":"59","author":"Figueras Nadal","year":"2003","journal-title":"An Pediatr (Barc)."},{"key":"10.1016\/j.riam.2021.04.002_bib0250","unstructured":"Gradoni L, L\u00f3pez-V\u00e9lez, Mokni M. World Health Organization. Manual on case management and surveillance of the leishmaniasis in the WHO European Region. Disponible en: https:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0006\/341970\/MANUAL-ON-CASE-MANAGEMENT_FINAL_with-cover-and-ISBN.pdf"},{"key":"10.1016\/j.riam.2021.04.002_bib0255","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijantimicag.2004.09.011","article-title":"Treatment of paediatric visceral leishmaniasis: Amphotericin B or pentavalent antimony compounds?","volume":"25","author":"Kafetzis","year":"2005","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.riam.2021.04.002_bib0260","doi-asserted-by":"crossref","first-page":"e2613","DOI":"10.1371\/journal.pntd.0002613","article-title":"Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: A randomised trial","volume":"8","author":"Khalil","year":"2014","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0265","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/INF.0000000000001602","article-title":"Short-course regimens of liposomal amphotericinB for the treatment of Mediterranean visceral leishmaniasis in children: An 11-year retrospective study at a tertiary care center","volume":"36","author":"Krepis","year":"2017","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.riam.2021.04.002_bib0270","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0163-4453(94)91643-8","article-title":"Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV","volume":"28","author":"Laguna","year":"1994","journal-title":"J Infect."},{"key":"10.1016\/j.riam.2021.04.002_bib0275","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jac\/dkh084","article-title":"Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients","volume":"53","author":"Lopez-Velez","year":"2004","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2021.04.002_bib0280","first-page":"197","article-title":"Liposomal amphotericinB and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS","volume":"12","author":"Mastroianni","year":"2004","journal-title":"Infez Med."},{"issue":"Suppl 3","key":"10.1016\/j.riam.2021.04.002_bib0285","doi-asserted-by":"crossref","first-page":"572s","DOI":"10.1016\/S0929-693X(00)80186-4","article-title":"Childhood visceral leishmaniasis in Provence","volume":"7","author":"Minodier","year":"2000","journal-title":"Arch Pediatr."},{"key":"10.1016\/j.riam.2021.04.002_bib0290","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.arcped.2005.01.009","article-title":"First-line liposomal amphotericinB for pediatric visceral leishmaniasis in southern France","volume":"12","author":"Minodier","year":"2005","journal-title":"Arch Pediatr."},{"key":"10.1016\/j.riam.2021.04.002_bib0295","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/dkm294","article-title":"Efficacy of liposomal amphotericinB for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients","volume":"60","author":"Molina","year":"2007","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2021.04.002_bib0300","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s40265-013-0133-0","article-title":"Therapeutic options for visceral leishmaniasis","volume":"73","author":"Monge-Maillo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.riam.2021.04.002_bib0305","first-page":"32","article-title":"Treatment options for visceral leishmaniasis and HIV coinfection","volume":"18","author":"Monge-Maillo","year":"2016","journal-title":"AIDS Rev."},{"key":"10.1016\/j.riam.2021.04.002_bib0310","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trstmh.2006.02.005","article-title":"Unresponsiveness to AmBisome in some Sudanese patients with kala-azar","volume":"101","author":"Mueller","year":"2007","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"10.1016\/j.riam.2021.04.002_bib0315","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Manual de procedimiento para la vigilancia y control de la leishmaniasis en las Am\u00e9ricas. Washington DC, 2019. Disponible en: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/50524\/9789275320631_spa.pdf?sequence=1&isAllowed=y"},{"key":"10.1016\/j.riam.2021.04.002_bib0320","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1093\/cid\/cir674","article-title":"Limited effectiveness of high-dose liposomal amphotericinB (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence","volume":"53","author":"Ritmeijer","year":"2011","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0325","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.medmal.2009.05.001","article-title":"Liposomal amphotericinB as treatment for visceral leishmaniasis in Europe","volume":"39","author":"Rosenthal","year":"2009","journal-title":"Med Mal Infect."},{"key":"10.1016\/j.riam.2021.04.002_bib0330","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/clinids\/21.1.188","article-title":"Liposomal amphotericinB (AmBisome) in the treatment of complicated kala-azar under field conditions","volume":"21","author":"Seaman","year":"1995","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0335","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4269\/ajtmh.2010.10-0156","article-title":"Effectiveness and safety of liposomal amphotericinB for visceral leishmaniasis under routine program conditions in Bihar India","volume":"83","author":"Sinha","year":"2010","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.riam.2021.04.002_bib0340","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/cid\/cir521","article-title":"Liposomal amphotericinB for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India","volume":"53","author":"Sinha","year":"2011","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0345","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericinB (AmBisome\u00ae): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs."},{"key":"10.1016\/j.riam.2021.04.002_bib0350","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.323.7310.419","article-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericinB: Randomised trial","volume":"323","author":"Sundar","year":"2001","journal-title":"BMJ."},{"key":"10.1016\/j.riam.2021.04.002_bib0355","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4269\/ajtmh.2002.66.143","article-title":"Low-dose liposomal amphotericinB in refractory Indian visceral leishmaniasis: A multicenter study","volume":"66","author":"Sundar","year":"2002","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.riam.2021.04.002_bib0360","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"AmphotericinB treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0365","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/591972","article-title":"New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphotericin B followed by short-course oral miltefosine","volume":"47","author":"Sundar","year":"2008","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0370","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericinB for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.riam.2021.04.002_bib0375","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: An open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.riam.2021.04.002_bib0380","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trstmh.2010.10.008","article-title":"Ambisome plus miltefosine for Indian patients with kala-azar","volume":"105","author":"Sundar","year":"2011","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"10.1016\/j.riam.2021.04.002_bib0385","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1086\/367843","article-title":"Two doses of a lipid formulation of amphotericinB for the treatment of Mediterranean visceral leishmaniasis","volume":"36","author":"Syriopoulou","year":"2003","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0390","first-page":"259","article-title":"Comparison of regimens of amphotericinB deoxycholate in kala-azar","volume":"103","author":"Thakur","year":"1996","journal-title":"Indian J Med Res."},{"key":"10.1016\/j.riam.2021.04.002_bib0395","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-8579(00)00312-5","article-title":"A single high dose treatment of kala-azar with Ambisome (amphotericinB lipid complex): A pilot study","volume":"17","author":"Thakur","year":"2001","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.riam.2021.04.002_bib0400","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1590\/S0036-46652009000400011","article-title":"Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment","volume":"51","author":"Velez","year":"2009","journal-title":"Rev Inst Med Trop Sao Paulo."},{"key":"10.1016\/j.riam.2021.04.002_bib0405","doi-asserted-by":"crossref","first-page":"e0004880","DOI":"10.1371\/journal.pntd.0004880","article-title":"Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: Phase II randomized trial","volume":"10","author":"Wasunna","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.riam.2021.04.002_bib0410","unstructured":"World Health Organization. WHO technical report series. Control of the leishmaniases. Report of a meeting of the WHO expert committee on the control of leishmaniases. Geneva, 2010. Disponible en: http:\/\/whqlibdoc.who.int\/trs\/WHO_TRS_949_eng.pdf"}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140621000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140621000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:08:04Z","timestamp":1761106084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140621000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1130140621000267"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2021.04.002","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2021.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Asociaci\u00f3n Espa\u00f1ola de Micolog\u00eda.","name":"copyright","label":"Copyright"}]}}